Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California Plans To Create Own Generics Label

Aiming To Regain Power From ‘Greedy’ Industry

Executive Summary

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

You may also be interested in...



California Governor Announces $100m Insulin Initiative

California is set to begin producing its own biosimilar insulin products, having been designated $100m by state governor Gavin Newsom to complete the project.

California Proceeds With Manufacturing Its Own Generics

With the legislature’s green light on California’s Generic Drug Pricing Bill, the state aims to manufacture generics while addressing shortages in the prescription drug market, expanding access to life-saving generic prescription drugs and improving patient health outcomes and overall public health. 

AAM Appeals Over California Pay-For-Delay Law

Responding to a California district court’s denial of an injunction to prevent the enactment of the US state’s legislation banning ‘pay-for-delay’ settlement deals, the AAM has confirmed plans to immediately appeal the decision.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel